


## DIAGNOSTICS FOR NEUROLOGICAL DISORDERS



# Enabling better patient journeys for suspected neurological conditions with Neurofilament Light Chain (NfL) testing

## Objective evidence of neuronal damage

Neurofilament Light Chain (NfL) is a well-studied blood biomarker test that is now widely available through Labcorp for assessing neuronal damage from neurodegenerative diseases and sports-related concussion. Labcorp is committed to developing and delivering innovative testing solutions to help support the evaluation and diagnosis of neurological disorders and diseases. NfL is our latest offering to support you in delivering meaningful insights to your patients faster.



Neurofilament light chain is a neuron specific protein that lines the axons of healthy neurons.



**Evaluating patients with suspected neurological disorders can be challenging. NfL testing can provide the necessary objective evidence that:**

- Increases your confidence in referring patients to a neurologist.
- Empowers you to give patients and their families better answers faster.

## NfL at a glance

Neurofilament light chain (NfL) is a neuron-specific protein routinely released into the extracellular space. Serum NfL levels rise above baseline in response to neuronal injury and neurodegeneration. NfL has been widely studied for various conditions<sup>1</sup>, and can be helpful for assessing patients for:

- Alzheimer's Disease and other neurodegenerative dementias: In symptomatic patients with subjective memory decline, NfL provides direct evidence for and can be a predictor of clinical progression<sup>2</sup>.
- Concussion recovery: NfL can be used, in conjunction with clinical observation, as a primary biomarker to assess return to play in concussed athletes<sup>3-5</sup>.
- Neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS)<sup>6,7</sup>, Multiple Sclerosis<sup>1,8</sup>, Parkinson's Disease<sup>9,10</sup>, and Spinocerebellar Ataxias<sup>11</sup>. In each of these, NfL, has been a predictor of disease progression.

## Labcorp Neurology

Our goal is to be your clinical and scientific partner in neurology. If you have an idea for a study utilizing NfL, we'd like to partner with you. Please send us an email at [LabcorpNeurology@labcorp.com](mailto:LabcorpNeurology@labcorp.com).

Test No.	Test Name
140455	Neurofilament Light Chain (NfL), Serum

For more details regarding specimen collection and test details, visit [labcorp.com/test-menu](https://labcorp.com/test-menu).



## Test Interpretation

NfL levels in healthy patients are known to increase with age<sup>12,13</sup>. Labcorp has established reference intervals by age groups to facilitate interpretation of NfL results.

## References

1. Khalil M, Teunissen CE, Otto M et al. Neurofilaments as biomarkers in neurological disorders. *Nat Rev Neurol*. 2018; 14(10):577-589.
2. Ebenau J, Pelkmans W, Verberk IMW, et al. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. *Neurology*. 2022, Publish Ahead of Print, DOI: 10.1212/WNL.0000000000200035.
3. Shahim P, Tegner Y, Marklund N, et al. Neurofilament light and tau as blood biomarkers for sports-related concussion. *Neurology*. 2018; 90:e1780-e1788.
4. McDonald SJ, O'Brien WT, Symons GF, et al. Prolonged elevation of serum neurofilament light after concussion in male Australian football players. *Biomarker Research*. 2021; 9:4.
5. Karantali E, Kazis D, McKenna J, et al. Neurofilament light chain in patients with a concussion or head impacts: a systematic review and meta-analysis. *European Journal of Trauma and Emergency Surgery*. 2021, 8 May. <https://doi.org/10.1007/s00068-021-01693-1>
6. Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery & Psychiatry*. 2019; 90:157-164.
7. Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. *Neurology*. 2018; 90:e22-30.
8. Thebault S, Booth RA, Rush CA et al. Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation. *Front Neurosci*. 2021 Mar 25; 15:654942
9. Lin CH, Li CH, Yang KC et al. Blood NfL: A biomarker for disease severity and progression in Parkinson disease. *Neurology*. 2019; 93(11):e1104-e1111.
10. Hallaway S, Desai P, Beck T, et al. Association of Neurofilament Light With the Development and Severity of Parkinson Disease. *Neurology*. 2022; 98:e2185-e2193.
11. Wilke C, Mengel D, Schöls L, et al. Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1. *Neurology*. 2022; 98 e1985-e1996.
12. Hviid CVB, Knudsen CS, and Parkner T. Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. *Scandinavian Journal of Clinical and Laboratory Investigation*. 2020; 80(4): 291-295.
13. Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. *Nature Communications*. 2020; 11:812.



For more information about NfL and how it can benefit your patients, contact your Labcorp sales representative, or visit [Labcorp.com/NfL](https://labcorp.com/NfL)

